A recent in vitro study shows that the synthesis of lipid droplet and the proliferation and migration of prostate cancer cells activated by the PPARγ pathway can be effectively promoted by low-dose rosiglitazone (59). The gene discussed is PPARG; the disease is prostate cancer.